Identity
Laboratorio Aldo-Union S.L.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €87k | |
| 2025 | €638k | |
| 2024 | €858k | |
| + regional platforms | ||
| 2023 | €178k | |
| 2022 | €125k | |
| 2021 | €171k | |
| 2020 | €2k | |
| 2019 | €<1k | |
| 2018 | €1k | |
In figures
Volume
Between 2018 and 2026 it won 194 contracts worth €2.06M on its own, with 7 buyers. Its joint-venture (UTE) contract is shown separately.
Price
In 2024–2026 its median discount was 41.4%; the middle half of its discounts between 25.6% and 42.3% (3 comparable awards).
Competition
Since 2024, 67% of its comparable value was won with a discount and against other bidders. It was the only bidder in 96% of its contracts (2018–2026).
Renewals
1 contract (€33.6k) comes up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Laboratorio Aldo-Union S.L.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Laboratorio Aldo-Union S.L.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
2024–2026: median 41.4% · middle half between 25.6% and 42.3% · 3 awards
Discount on the tender budget, excluding VAT, on awards above the minor-contract threshold · Source: official data, national and regional coverage. Methodology →
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
How it wins
Whether it wins with or without competition.
67% of the comparable value since 2024 (€328k of €488k) was won with a discount and against other bidders. €94.3k (19%) was awarded with a discount and without other bidders.
Comparable: 6 awards with a published budget and bidder count (€488k of €1.58M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2018 and 2026, 74.2% of the value was awarded through open procedure (52.3% of contracts); followed by Based on a framework agreement (23.2%) and Negotiated without publicity (2.6%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 1 of its contracts comes up for tender again, worth €33.6k.
| Expected end | Buyer | Value |
|---|---|---|
| 2027 | OSAKIDETZA - Servicio Vasco de Salud -Director General | €33.6k |
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| Gerencia de Servicio Sanitarios de Fuerteventura | 180 | 1.3 M | 2020–2025 |
| Servicio Murciano de Salud - Junta de Compras | 4 | 435 k | 2024 |
| OSAKIDETZA - Servicio Vasco de Salud -Director General | 2 | 265 k | 2025–2026 |
| Consorci Corporació Sanitària Parc Taulí de Sabadell | 2 | 54 k | 2026 |
| Fundació de Gestió Sanitària de l'Hospital de la Santa Creu i Sant Pau | 1 | 49 k | 2024 |
and 2 more buyers
Between 2018 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 192 contracts).
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 29/10/2025 | Suministro de Doxorubicina Liposomal (DOE), Ceftriaxona (DOE), Meropenem (DOE), Asociación Ipratrop… | OSAKIDETZA - Servicio Vasco de Salud -Director General | 1 | €231k |
| 13/08/2025 | LOTE 202. Budesonida 0.5 Mg/Ml 2 Ml Solucion para Nebulizacion Inhalatoria _ Contratación con la em… | Dirección Gerencia del Complejo Hospitalario Universitario de Canarias | 1 | €7.96k |
| 13/08/2025 | LOTE 201. Budesonida 0.25 Mg/Ml 2 Ml Solucion para Nebulizacion Inhalatoria _ Contratación con la e… | Dirección Gerencia del Complejo Hospitalario Universitario de Canarias | 1 | €2.96k |
| 13/08/2025 | LOTE 203. Budesonida 200 Mcg/Dos 200 Dosis Nebulizacion Inhalatoria_ Contratación con la empresa_ L… | Dirección Gerencia del Complejo Hospitalario Universitario de Canarias | 1 | €14.2k |
| 13/08/2025 | LOTE 204. Ipratropio Bromuro 20 Mcg/Pul 200 Dosis Inhalatoria_ Contratación con la empresa_ LABORAT… | Dirección Gerencia del Complejo Hospitalario Universitario de Canarias | 1 | €17.2k |